SUPERSEDED LCD Reference Article	Billing and Coding Article
----------------------------------	----------------------------

Article - Billing and Coding: MoIDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57422)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Superseded

To see the currently-in-effect version of this document, go to the <u>Public Versions</u> section.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATES
Noridian Healthcare Solutions, LLC	A and B MAC	02101 - MAC A	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02102 - MAC B	J - F	Alaska
Noridian Healthcare Solutions, LLC	A and B MAC	02201 - MAC A	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02202 - MAC B	J - F	Idaho
Noridian Healthcare Solutions, LLC	A and B MAC	02301 - MAC A	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02302 - MAC B	J - F	Oregon
Noridian Healthcare Solutions, LLC	A and B MAC	02401 - MAC A	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	02402 - MAC B	J - F	Washington
Noridian Healthcare Solutions, LLC	A and B MAC	03101 - MAC A	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03102 - MAC B	J - F	Arizona
Noridian Healthcare Solutions, LLC	A and B MAC	03201 - MAC A	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03202 - MAC B	J - F	Montana
Noridian Healthcare Solutions, LLC	A and B MAC	03301 - MAC A	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03302 - MAC B	J - F	North Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03401 - MAC A	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03402 - MAC B	J - F	South Dakota
Noridian Healthcare Solutions, LLC	A and B MAC	03501 - MAC A	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03502 - MAC B	J - F	Utah
Noridian Healthcare Solutions, LLC	A and B MAC	03601 - MAC A	J - F	Wyoming
Noridian Healthcare Solutions, LLC	A and B MAC	03602 - MAC B	J - F	Wyoming

Article Information

General Information

Article ID

A57422

Article Title

Billing and Coding: MoIDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease

Article Type

Billing and Coding

Original Effective Date

11/01/2019

Revision Effective Date

01/01/2024

Revision Ending Date

09/30/2024

Retirement Date

N/A

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB\(\text{UB}\)04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312\(\text{SB}\)893\(\text{B816}\).

Making copies or utilizing the content of the UB□04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB□04 Manual and/or codes and descriptions; and/or making any commercial use of UB□04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

CMS National Coverage Policy

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

CMS Internet-Only Manual, Publication 100-04, *Medicare Claims Processing Manual*, Chapter 16, §50.5 Jurisdiction of Laboratory Claims, §60.1.1 Independent Laboratory Specimen Drawing, §60.2. Travel Allowance.

CMS Internet-Only Manual, Publication 100-04 Medicare Claims Processing Manual, Chapter 23, §10 Reporting ICD Diagnosis and Procedure Codes.

CMS Internet-Only Manual, Publication 100-04 Medicare Claims Processing Manual, Chapter 12, §30 Correct Coding Policy.

Article Guidance

Article Text

The information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MoIDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease L36186. For single

genes performed by NGS, these tests must demonstrate compliance with L38125 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies and its accompanying billing and coding article, A56518 Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer.

To report Genetic Testing for BCR-ABL Negative Myeloproliferative Disease service, please submit the following claim information:

- Select appropriate CPT[®] code
- Enter 1 unit of service (UOS)
- Enter the appropriate DEX Z-Code® identifier adjacent to the CPT® code in the comment/narrative field for the following Part B claim field/types:
 - Loop 2400 or SV101-7 for the 5010A1 837P
 - Item 19 for paper claim
- Enter the appropriate DEX Z-Code® identifier adjacent to the CPT® code in the comment/narrative field for the following Part A claim field/types:
 - Line SV202-7 for 837I electronic claim
 - Block 80 for the UB04 claim form
- Select the appropriate ICD-10-CM code

NOTE: When entering the DEX Z- $Code^{\mathbb{R}}$ on the SV101-7 documentation field for Part B claims please do not add additional characters and/or information on the line.

Coding Information

CPT/HCPCS Codes

Group 1 Paragraph:

N/A

Group 1 Codes: (12 Codes)

CODE	DESCRIPTION
81206	BCR/ABL1 (T(9;22)) (EG, CHRONIC MYELOGENOUS LEUKEMIA) TRANSLOCATION ANALYSIS; MAJOR BREAKPOINT, QUALITATIVE OR QUANTITATIVE
81207	BCR/ABL1 (T(9;22)) (EG, CHRONIC MYELOGENOUS LEUKEMIA) TRANSLOCATION ANALYSIS; MINOR BREAKPOINT, QUALITATIVE OR QUANTITATIVE
81208	BCR/ABL1 (T(9;22)) (EG, CHRONIC MYELOGENOUS LEUKEMIA) TRANSLOCATION ANALYSIS; OTHER BREAKPOINT, QUALITATIVE OR QUANTITATIVE
81219	CALR (CALRETICULIN) (EG, MYELOPROLIFERATIVE DISORDERS), GENE ANALYSIS, COMMON VARIANTS IN EXON 9
81270	JAK2 (JANUS KINASE 2) (EG, MYELOPROLIFERATIVE DISORDER) GENE ANALYSIS, P.VAL617PHE (V617F) VARIANT

CODE	DESCRIPTION
81279	JAK2 (JANUS KINASE 2) (EG, MYELOPROLIFERATIVE DISORDER) TARGETED SEQUENCE ANALYSIS (EG, EXONS 12 AND 13)
81338	MPL (MPL PROTO-ONCOGENE, THROMBOPOIETIN RECEPTOR) (EG, MYELOPROLIFERATIVE DISORDER) GENE ANALYSIS; COMMON VARIANTS (EG, W515A, W515K, W515L, W515R)
81339	MPL (MPL PROTO-ONCOGENE, THROMBOPOIETIN RECEPTOR) (EG, MYELOPROLIFERATIVE DISORDER) GENE ANALYSIS; SEQUENCE ANALYSIS, EXON 10
81450	HEMATOLYMPHOID NEOPLASM OR DISORDER, GENOMIC SEQUENCE ANALYSIS PANEL, 5-50 GENES, INTERROGATION FOR SEQUENCE VARIANTS, AND COPY NUMBER VARIANTS OR REARRANGEMENTS, OR ISOFORM EXPRESSION OR MRNA EXPRESSION LEVELS, IF PERFORMED; DNA ANALYSIS OR COMBINED DNA AND RNA ANALYSIS
81479	UNLISTED MOLECULAR PATHOLOGY PROCEDURE
0027U	JAK2 (JANUS KINASE 2) (EG, MYELOPROLIFERATIVE DISORDER) GENE ANALYSIS, TARGETED SEQUENCE ANALYSIS EXONS 12-15
0040U	BCR/ABL1 (T(9;22)) (EG, CHRONIC MYELOGENOUS LEUKEMIA) TRANSLOCATION ANALYSIS, MAJOR BREAKPOINT, QUANTITATIVE

$\cap DT$	HCDCC	Modifiers

Group 1 Paragraph:

N/A

Group 1 Codes:

N/A

ICD-10-CM Codes that Support Medical Necessity

Group 1 Paragraph:

N/A

Group 1 Codes: (34 Codes)

CODE	DESCRIPTION	
C88.8	Other malignant immunoproliferative diseases	
C91.00	Acute lymphoblastic leukemia not having achieved remission	
C91.01	Acute lymphoblastic leukemia, in remission	
C91.02	Acute lymphoblastic leukemia, in relapse	

CODE	DESCRIPTION	
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	
C93.10	Chronic myelomonocytic leukemia not having achieved remission	
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	
C94.41	Acute panmyelosis with myelofibrosis, in remission	
C94.42	Acute panmyelosis with myelofibrosis, in relapse	
C94.6	Myelodysplastic disease, not elsewhere classified	
D45	Polycythemia vera	
D46.0	Refractory anemia without ring sideroblasts, so stated	
D46.1	Refractory anemia with ring sideroblasts	
D46.21	Refractory anemia with excess of blasts 1	
D46.22	Refractory anemia with excess of blasts 2	
D46.A	Refractory cytopenia with multilineage dysplasia	
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	
D46.Z	Other myelodysplastic syndromes	
D47.02	Systemic mastocytosis	
D47.1	Chronic myeloproliferative disease	
D47.3	Essential (hemorrhagic) thrombocythemia	
D47.4	Osteomyelofibrosis	
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	
D72.821	Monocytosis (symptomatic)	
D75.1	Secondary polycythemia	
D75.81	Myelofibrosis	
D75.838	Other thrombocytosis	
D75.89	Other specified diseases of blood and blood-forming organs	

Group 1 Paragraph:		
N/A		
Group 1 Codes:		
N/A		
ICD-10-PCS Codes		
Group 1 Paragraph:		
N/A		
Group 1 Codes:		
N/A		

ICD-10-CM Codes that DO NOT Support Medical Necessity

Bill Type Codes

Additional ICD-10 Information

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the article does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the article should be assumed to apply equally to all claims.

N/A

N/A

Revenue Codes

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the article, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the article should be assumed to apply equally to all Revenue Codes.

N/A

Other Coding Information

Group 1 Paragraph:

N/A		
Group 1 Codes:		
N/A		

Revision History Information

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
01/01/2024	R10	Under CPT/HCPCS Codes Group 1: Codes the description was revised for 81450. This revision is due to the 2024 Annual/Q1 CPT/HCPCS Code Update and is effective 1/1/2024.
		Under CMS National Coverage Policy updated section heading for 2nd regulation. Under Article Text revised 3rd and 6th bullets to remove "DEX Z-Code™" and replaced with "DEX Z-Code®". Added " NOTE : When entering the DEX Z-Code® on the SV101-7 documentation field for Part B claims please do not add additional characters and/or information on the line". This revision is effective 1/1/2024.
01/01/2023	R9	Updated to indicate this article is an LCD Reference Article.
01/01/2023	R8	Under CPT/HCPCS Codes Group 1: Codes the description was revised for 81450. This revision is due to the 2023 Annual/Q1 CPT/HCPCS Code Update and is retroactive effective for dates of service on or after 1/1/2023.
10/01/2022	R7	Under ICD-10 Codes that Support Medical Necessity Group 1: Codes the description was revised for C94.6. This revision is due to the Annual ICD-10-CM Update and will become effective on 10/1/2022.
03/17/2022	R6	Under Article Text added verbiage, "For single genes performed by NGS, these tests must demonstrate compliance with L38125 MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies and its accompanying billing and coding article, A56518 Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer." This revision is effective on 03/17/2022.
10/01/2021	R5	Under ICD-10-CM Codes that Support Medical Necessity Group 1: Codes added D75.838. This revision is due to the Annual ICD-10 Update and will become effective on 10/1/21.
07/01/2021	R4	Under CPT/HCPCS Codes Group 1: Code added 0040U. This revision is due to the

REVISION HISTORY DATE	REVISION HISTORY NUMBER	REVISION HISTORY EXPLANATION
		code being previously omitted in error and is retroactive effective for date of service on or after 01/13/2020.
07/01/2021	R3	Under CMS National Coverage Policy moved CMS Internet-Only Manual, Pub. 100-02, Medicare Benefit Policy Manual, Chapter 15 §80 Requirements for Diagnostic X-Ray, Diagnostic Laboratory, and Other Diagnostic Tests to the related LCD.
		Under ICD-10 Codes that Support Medical Necessity Group 1: Codes deleted D46.20, D46.4, D46.9, D47.9, D72.829, and D75.9.
01/01/2021	R2	Under CPT/HCPCS Codes Group 1: Codes added 0027U and deleted 81402. Deleted CPT/HCPCS Codes Group 2 Paragraph and CPT/HCPCS Codes Group 2: Codes including 81403, 81445, 81455. Due to the deletion of CPT/HCPCS Codes Group 2: Codes 81450 was moved to CPT/HCPCS Codes Group 1: Codes.
		Under ICD-10 Codes that Support Medical Necessity Group 1: Paragraph deleted the verbiage, "Group 1 CPT codes and Group 2 CPT codes apply to Group 1 ICD-10 Codes". This revision is retroactive effective for dates of service on or after 1/1/2021.
		Under CPT/HCPCS Codes Group 1: Codes added 81279, 81338 and 81339. This revision is due to the Q1 2021 CPT/HCPCS Code Update and is retroactive effective for dates of service on or after 1/1/2021
11/07/2019	R1	Article is revised to add CMS references.
		Under CPT/HCPCS Codes Group 1: Codes deleted CPT $^{\mathbb{R}}$ codes 81403, 81445, 81450, and 81455. Under CPT/HCPCS Codes Group 2: Paragraph added verbiage, "CPT $^{\mathbb{R}}$ codes that are also referenced in other articles". Under CPT/HCPCS Group 2: Codes added CPT $^{\mathbb{R}}$ codes 81403, 81445, 81450, and 81455.

Associated Documents

Related Local Coverage Documents

LCDs

<u>L36186 - MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease</u>

Related National Coverage Documents

N/A

Statutory Requirements URLs

N/A

Rules and Regulations URLs

N/A

CMS Manual Explanations URLs

N/A

Other URLs

N/A

Public Versions

UPDATED ON	EFFECTIVE DATES	STATUS	
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.			
09/03/2024	10/01/2024 - N/A	Future Effective	
01/23/2024	01/01/2024 - 09/30/2024	Currently in Effect (This Version)	
11/22/2023	01/01/2023 - 12/31/2023	Superseded	
01/11/2023	01/01/2023 - N/A	Superseded	

Keywords

N/A